newsfilter
← Latest News
GlobeNewswire·

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223)